Skip to main content
  • Notice of Privacy Incident
  • Medicaid Provider Termination Alert: Revalidation deadlines are approaching. Failure by providers to revalidate will lead to termination and payment suspension. Check your account now at https://impact.illinois.gov/ to learn if your required revalidation is due this month. More revalidation information here.
Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: September 15, 2010

Drug Name Review Type Class Manufacturer
Zirgan New Drug Initial Review Antiviral Bausch & Lomb
Oravig New Drug Initial Review Antifungal Strativa
Cetraxal New Drug Initial Review Otic Antibiotic Wraser
Lysteda New Drug Initial Review Antifibrinolytic Ferring
Oleptro New Drug Initial Review Antidepressant Labopharm
Pancreaze New Drug Initial Review Pancreatic Enzyme OMJPI
Xifaxan 550 New Drug Appeal Antibiotic Salix
Bepreve New Drug Appeal Ophthalmic- Allergic Conjunctivitis Ista
Colcrys New Drug Appeal Anti-Gout URL
Fanapt New Drug Appeal Atypical Antipsychotic Novartis
Pristiq New Drug Appeal SNRI Antidepressant Pfizer
Saphris PDL Appeal Atypical Antipsychotic Merck
Vesicare PDL Appeal Urinary Anti-Incontinence Astellas